

## SUPPLEMENTARY TABLES

**Supplementary Table 1. Clinicopathologic characteristics of HCC patients (n=371).**

---

<b>Age at diagnosis (years)</b>	
≤ 50	81
> 50	290
<b>Gender</b>	
Male	121
Female	250
<b>T</b>	
T1	181
T2	94
T3	80
T4	13
TX	3
<b>N</b>	
N0	252
N1	4
NX	115
<b>M</b>	
M0	266
M1	4
MX	101
<b>Grade</b>	
G1	55
G2	177
G3	122
G4	12
unknown	5
<b>Vital status</b>	
Alive	240
Dead	130
<b>Median follow-up (Months)</b>	19.4

---

HCC, hepatocellular carcinoma.

**Supplementary Table 2. siRNAs and antibodies used in the study.**

<b>SiRNAs</b>		
ACSL3	Ruibo Biotechnology Co., Ltd. (Guangzhou, China)	siG000002181A-1-5
ADH1B	Ruibo Biotechnology Co., Ltd. (Guangzhou, China)	siG1452893545-1-5
ALDH2	Ruibo Biotechnology Co., Ltd. (Guangzhou, China)	siG000000217A-1-5
HADHA	Ruibo Biotechnology Co., Ltd. (Guangzhou, China)	siG000003030A-1-5
<b>Antibodies</b>		
ACSL3	Proteintech, Wuhan, China	20710-1-AP
ADH1B	Proteintech, Wuhan, China	17165-1-AP
ALDH2	Proteintech, Wuhan, China	15310-1-AP
HADHA	Proteintech, Wuhan, China	10758-1-AP

HCC, hepatocellular carcinoma.